Needham Reiterates Buy on RxSight, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst David Saxon has reiterated a Buy rating on RxSight (NASDAQ:RXST) and maintained a $64 price target.

April 11, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst David Saxon reiterates a Buy rating on RxSight with a maintained price target of $64.
The reiteration of a Buy rating by a reputable analyst, along with the maintenance of a high price target, suggests a positive outlook on RxSight's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100